Anteris Technologies Postpones Special Meeting of Stockholders to Sept. 11.

Anteris Technologies Global Corp. has postponed its Special Meeting of Stockholders, originally scheduled for September 4, 2025, to September 11, 2025. The meeting will now be held virtually via live webcast. The company is a global structural heart company focused on designing and developing medical devices to restore heart function.

Anteris Technologies Global Corp. (Anteris or the Company) has announced the postponement of its Special Meeting of Stockholders from September 4, 2025, to September 11, 2025. The meeting, originally scheduled to be held at 5:00 p.m. Central time (8:00 a.m. AEST on Friday, September 5, 2025), will now be held virtually via live webcast at [www.virtualshareholdermeeting.com/AVR2025SM](http://www.virtualshareholdermeeting.com/AVR2025SM). The record date for the Special Meeting, August 11, 2025, remains unchanged and applies to the postponed meeting.

The postponement aims to provide stockholders with additional time to vote, thereby facilitating broader participation. The company's Board of Directors unanimously recommends that shareholders vote FOR the proposals identified in the Company's definitive Proxy Statement for the Special Meeting, which was filed with the Securities and Exchange Commission (SEC) on August 18, 2025.

Shareholders who have already voted their shares of Common Stock or directed CHESS Depositary Nominees Pty Ltd (CDN) to vote their CHESS Depositary Interests (CDIs) by completing the CDI Voting Instruction Form do not need to take any additional action as their prior vote will remain voted. Those who held shares of Common Stock on the Record Date and have not yet voted can now do so using the directions provided in the Proxy Statement. Proxies must be received by 11:59 p.m. Eastern time on September 10, 2025 (1:59 p.m. AEST on September 11, 2025), or by the close of business on September 10, 2025 (7:00 a.m. AEST on September 11, 2025), to be counted prior to the Special Meeting.

For CDI holders who have not yet directed CDN to vote, the completed CDI Voting Instruction Form must be submitted to Computershare, the agent designated for the collection and processing of voting instructions, prior to 5:00 p.m. Central time on September 9, 2025 (8:00 a.m. AEST on September 10, 2025).

The Company's Proxy Statement, filed with the SEC on August 18, 2025, should be read in conjunction with this notice. Stockholders are urged to read the Proxy Statement and any other relevant documents filed with the SEC carefully and in their entirety because they contain important information about any solicitation.

Anteris Technologies Global Corp., a global structural heart company, is committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. The company's lead product, the DurAVR® Transcatheter Heart Valve (THV), is designed in partnership with leading interventional cardiologists and cardiac surgeons to treat aortic stenosis, a potentially life-threatening condition resulting from the narrowing of the aortic valve.

For more information, contact Investor Relations at Debbie Ormsby or Malini Chatterjee, Ph.D. at +61 1300 550 310, +61 7 3152 3200, or +1 917 330 4269.

References:
1. [Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders](https://www.nasdaq.com/press-release/anteris-technologies-global-corp-announces-postponement-special-meeting-stockholders)
2. [Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders](https://financialpost.com/globe-newswire/anteris-technologies-global-corp-announces-postponement-of-special-meeting-of-stockholders)